Beach Investment Counsel Inc. PA decreased its position in Roche Holding Ltd. (NASDAQ:RHHBY) by 12.1% during the second quarter, Holdings Channel reports. The firm owned 118,422 shares of the company’s stock after selling 16,272 shares during the period. Beach Investment Counsel Inc. PA’s holdings in Roche Holding were worth $3,891,000 as of its most recent SEC filing.
A number of other institutional investors have also recently modified their holdings of RHHBY. Sterling Capital Management LLC boosted its stake in shares of Roche Holding by 19.1% in the second quarter. Sterling Capital Management LLC now owns 19,085 shares of the company’s stock worth $627,000 after buying an additional 3,056 shares in the last quarter. Wunderlich Capital Managemnt boosted its stake in shares of Roche Holding by 2.5% in the second quarter. Wunderlich Capital Managemnt now owns 40,510 shares of the company’s stock worth $1,335,000 after buying an additional 977 shares in the last quarter. Finally, Sky Investment Group LLC boosted its stake in shares of Roche Holding by 1.4% in the second quarter. Sky Investment Group LLC now owns 77,136 shares of the company’s stock worth $2,542,000 after buying an additional 1,072 shares in the last quarter.
Roche Holding Ltd. (NASDAQ:RHHBY) opened at 29.61 on Monday. Roche Holding Ltd. has a 52 week low of $28.10 and a 52 week high of $35.13. The company has a 50-day moving average of $29.75 and a 200-day moving average of $31.21. The stock has a market cap of $201.86 billion and a P/E ratio of 22.34.
A number of research analysts recently weighed in on the stock. Zacks Investment Research cut shares of Roche Holding from a “buy” rating to a “hold” rating in a report on Tuesday, July 19th. Citigroup Inc. restated a “buy” rating on shares of Roche Holding in a report on Wednesday, August 3rd.
About Roche Holding
Roche Holding AG is a research-based healthcare company. The Company develops, manufactures and delivers medicines, and diagnostic instruments and tests. Its operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. Its Pharmaceuticals division consists of two business segments: Roche Pharmaceuticals and Chugai.